Tests resveratrol added to standard treatment in adults with rheumatoid arthritis
Tests resveratrol with usual treatment in adults with moderate rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.
Key facts
- Where
- Cairo, EgyptSee the site
Where in Egypt
- Department of Rheumatology at Ain Shams university hospital, Cairo, EgyptCairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ain Shams University
- Trial code
- NCT07089381
- Record updated
- 28 July 2025
- Original description
The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis.Read full original descriptionShow less
Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.
The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis.
Objectives :
1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring:
* Serum Sirtuin 1(SIRT1) * Serum Myeloperoxidase (MPO) * Serum C-reactive protein (CRP) 2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score). 3. To investigate the effect of Resveratrol on improving the quality of life using the Health Assessment Questionnaire Disability index (HAQ-DI). 4. To assess any adverse effects related to Resveratrol.
Patients:
Eligible patients (no=118) will be randomly assigned in a 1:1 ratio to one of two groups:
1. Control group: 59 patients will receive the standard treatment for management of RA for 3 months. 2. Resveratrol group: 59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix Egypt) (given as one 1000 mg tablets once daily) for 3 months.
Inclusion: Adult patients > 18 years old; Established diagnosis of RA according to American College of Rheumatology/European league Against Rheumatism (ACR/EULAR) 2010 criteria (Aletaha et al., 2010), presented with moderate to high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) >3.2; Patients receiving stable regimen of one or more csDMARDs for at least the past 3 months; RA Patients with Moderate or high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) >3.2.
Exclusion: Patients receiving biologic DMARDs therapy for RA; Patients taking any other anti-inflammatory drugs; Other rheumatological, inflammatory diseases or malignancies; Thyroid illnesses; Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) < 30 ml/min); Patients taking any other antioxidants; Pregnant and lactating women; Smokers.